

REMARKS

Applicants confirm the election of claims 1-18 and 23-25. Applicants request rejoinder of claims 19-21 once the claims on which they depend are found to be allowable. Claims 19-21 define a method of claim 18 with an additional step of administering an anti-cancer compound or composition other than that defined in claim 1. Such method will incorporate a novel and obvious process once claim 18 is allowed such that it would not be an undue burden to examine the methods of claims 19-21.

OBJECTION TO THE SPECIFICATION

A new abstract has been presented and the title of the application has been amended in response to the objection to the specification.

Claims 18 and 22 have been amended to recite only the treatment of a hyper-proliferative disorder, osteoporosis, inflammation and angiogenesis disorders to expedite prosecution. Applicants maintain the specification does provide sufficient disclosure to enable any person skilled in the art to perform the methods for the prevention of these diseases. High-risk candidates for these diseases can be identified and the claimed compounds can be administered in a manner consistent with treatment methods without undue experimentation.

DOUBLE PATENTING

Claims 17, 18 and 23-25 are not in conflict with claims 69-109 and 50-54 of application Serial No. 10/042,203. Claims 17, 18 and 22-25 define, respectively :

- (1) a pharmaceutical composition containing a compound of claim 1,
- (2) a method of treating a hyper-proliferative disorder with a compound of claim 1,
- (3) a method of treating osteoporosis, inflammation and angiogenesis disorders with a compound of claim 1,


- (4) a method of treating liver cancer with a compound of claim 1,
- (5) a method of treating specific liver cancers with a compound of claim 1 and
- (6) a pharmaceutically acceptable salt of a compound of claim 1.

The compounds of claim 1 require at least one of X^1 to X^7 be hydroxy or $-OC(O)C_1-C_4$. The substituents on the compounds defined in the claims identified in Serial No.10/042203 comprise the following: tert-butyl, methylcarbamoyl, methoxy, carbamoyl, trifluoromethyl and chloro. These compounds are not substituted by hydroxy or $-OC(O)C_1-C_4$. Therefore, this rejection should be withdrawn.

Based on the above remarks, Applicants submit that all claims are now in condition for allowance.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 15P4

Date: March 10, 2003

RJT/jqs
K:\Bayer\15P4\prel.amend 5-21-02.doc


VERSION WITH MARKINGS TO SHOW CHANGES MADE

18. (Amended) A method of treating ~~or preventing~~ a hyper-proliferative disorder in a mammal by administering an effective amount of a compound of claim 1 to said mammal.

22. (Amended) A method of treating ~~or preventing~~ osteoporosis, inflammation, and angiogenesis disorders, with the exclusion of cancer, in a mammal by administering an effective amount of a compound of claim 1 to said mammal.

ABSTRACT OF THE DISCLOSURE

B¹
T, 9000
The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula



wherein,

Y is NHR

Hal is chlorine or bromine,

R is H, CH₃ or CH₂OH, and

X¹ to X⁷ are each, independently, H, OH or -OC(O)C₁-C₄ alkyl, or a salt purified

stereoisomer thereof,

wherein at least one of X¹ to X⁷ is OH or -OC(O)C₁-C₄ alkyl.